Summary of Corcept Therapeutics Q3 2025 Earnings Call

1Key Financial Results and Metrics

Revenue: $207.6 million for Q3 2025, up from $182.5 million in Q3 2024.

Net Income: $19.7 million, significantly down from $47.2 million in the prior year.

Cash and Investments: $524 million as of September 30, 2025, reflecting a $50 million stock repurchase.

Revised Revenue Guidance: Adjusted to $800 million to $850 million for 2025.

2Strategic Updates and Business Highlights

Hypercortisolism Business Growth: Record shipments of Korlym, with a 42.5% increase in tablets shipped compared to last year. The prescriber base has expanded significantly.

Pharmacy Transition: Transitioning to a new pharmacy (Curant) due to capacity issues with the previous vendor. A second specialty pharmacy is planned for January 2026.

Clinical Developments:

NDA for relacorilant for hypercortisolism has a PDUFA date of December 30, 2025.

NDA for relacorilant in platinum-resistant ovarian cancer has a PDUFA date of July 11, 2026.

Upcoming results expected from multiple trials, including MOMENTUM and ROSELLA.

Oncology Expansion: Plans to broaden oncology studies beyond ovarian cancer, including trials for endometrial and pancreatic cancers.

3Forward Guidance and Outlook

Growth Expectations: Anticipate continued growth in the hypercortisolism market, with expectations that relacorilant could generate $3 billion to $5 billion in annual revenue within 3-5 years.

Q4 Revenue Expectations: Projected revenue growth of approximately 28% from Q3 to Q4, aiming for around $265 million in Q4 sales.

R&D and SG&A Spending: R&D expenditures expected to remain stable, while SG&A expenses will increase to support product launches and clinical studies.

4Bad News, Challenges, or Points of Concern

Declining Net Income: A notable decrease in net income compared to the previous year raises concerns about profitability amidst increasing revenues.

Capacity Constraints: Ongoing capacity issues with the previous pharmacy vendor may affect short-term growth, although the new pharmacy is expected to alleviate these issues.

Patent Litigation: Uncertainty surrounding the ongoing patent litigation with Teva Pharmaceuticals, which could impact market dynamics if not resolved favorably.

5Notable Q&A Insights

Patient Base: Approximately 3,250 paying patients on Korlym as of the end of Q3.

Capacity of New Pharmacy: Curant is fully operational and expected to handle increased volume effectively.

Authorized Generic Sales: Over 70% of sales now come from the authorized generic, with a projected increase to around 75% by year-end.

Regulatory Insights: The company had both mid-cycle and late-cycle reviews for relacorilant, with confidence in meeting the FDA's target date for approval. Overall, Corcept Therapeutics is positioned for growth with significant upcoming product launches and a strong pipeline, despite facing challenges related to profitability and capacity constraints.